NDA 050162 · Pfizer
Cleocin Hydrochloride
Clindamycin Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1970
Feb 22, 1970
Approved uses
4
Original approval plus efficacy supplements
Registered trials
274
66 Phase 3, 28 recruiting
FAERS reports
3,695
2,818 serious, 243 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Clostridioides difficile infection (CDI) has been reported with use of nearly all antibacterial agents, including CLEOCIN HCl and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. Because CLEOCIN HCl therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B, which contribute to the development of CDI. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy...
What it is approved for
From the label in effect Sep 16, 2026.
INDICATIONS AND USAGE Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN HCl and other antibacterial drugs, CLEOCIN HCl should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and...
Mechanism: Mechanism of Action Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 14, 1988 Supplement 11 · Efficacy
- Nov 3, 1981 Supplement 76 · Efficacy
- May 22, 1970 Supplement 1 · Efficacy
- Feb 22, 1970 Original approval
3 products under this application
- CLEOCIN HYDROCHLORIDE · CLINDAMYCIN HYDROCHLORIDE EQ 300MG BASE · CAPSULE, ORAL · Prescription · TE AB
- CLEOCIN HYDROCHLORIDE · CLINDAMYCIN HYDROCHLORIDE EQ 75MG BASE · CAPSULE, ORAL · Prescription · TE AB
- CLEOCIN HYDROCHLORIDE · CLINDAMYCIN HYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
University of OxfordAcademic, hospital or other
NCT04093765 · 5,542 participants · Start Nov 1, 2018 · Primary completion Dec 31, 2019
Drug: Antimalarials · For: Plasmodium Falciparum Malaria
Sites: Mae Sot, Thailand
- Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial VaginosisPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT00642980 · 3,105 participants · Start Apr 2006 · Primary completion Jun 2011
Drug: Clindamycin; Placebo and 1 more · For: Pregnancy
Sites: Lille, France
- Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00729937 · 2,265 participants · Start Apr 2009 · Primary completion May 2013
Drug: Cephalexin; Clindamycin and 1 more · For: Staphylococcal Infection
Sites: Phoenix, Arizona; Sylmar, California; Baltimore, Maryland · 5 sites in all
- Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated MalariaPivotal-lookingCompleted
Universiteit AntwerpenAcademic, hospital or other
NCT01374581 · 2,117 participants · Start May 2012 · Primary completion Jun 2014
Drug: Artemether/Lumefantrine; Artesunate/Amodiaquine and 1 more · For: Malaria
Sites: Kinshasa, Republic of the Congo; Kiruhura, Uganda
- Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean InfectionPivotal-lookingCompleted
Alan TitaAcademic, hospital or other
NCT01235546 · 2,013 participants · Start May 2011 · Primary completion Dec 2015
Drug: Azithromycin and standard of care; Placebo and standard of care · For: Endometritis; Wound Infection; Abscess and 1 more
Sites: Birmingham, Alabama; New Orleans, Louisiana; Jackson, Mississippi · 9 sites in all
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center TrialPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03283878 · 1,770 participants · Start Oct 24, 2017 · Primary completion Nov 20, 2024
Drug: Cefazolin · For: Arthropathy of Knee; Antibiotic Prophylaxis
Sites: San Francisco, California; Atlanta, Georgia; Towson, Maryland · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea293
- rash278
- nausea258
- off label use257
- pain232
- dyspnoea212
- drug ineffective211
- drug hypersensitivity197
- headache181
- pruritus179
- fatigue168
- arthralgia158
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 34 |
| 2005 | 80 |
| 2006 | 52 |
| 2007 | 43 |
| 2008 | 55 |
| 2009 | 50 |
| 2010 | 44 |
| 2011 | 61 |
| 2012 | 91 |
| 2013 | 40 |
| 2014 | 28 |
| 2015 | 51 |
| 2016 | 123 |
| 2017 | 83 |
| 2018 | 105 |
| 2019 | 153 |
| 2020 | 173 |
| 2021 | 224 |
| 2022 | 444 |
| 2023 | 440 |
| 2024 | 537 |
| 2025 | 462 |
| 2026 | 322 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Feb 25, 2026
Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Feb 25, 2026
Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Feb 25, 2026
Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Linezolid versus clindamycin for toxin inhibition in severe skin and soft tissue infections: a systematic review and meta-analysis.
Stropes A, Lautenschlager C, Smith A, et al. · Infection 2026 · Systematic Review, Meta-Analysis
- Antibiotic regimens for postpartum endometritis.
Mackeen AD, Packard RE, Ota E, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.
Parks T, Wilson C, Curtis N, et al. · Clin Infect Dis 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis.
Bartoszko JJ, Elias Z, Rudziak P, et al. · BMJ Open 2022 · Meta-Analysis, Systematic Review
- Efficacy of prophylactic antibiotics for preterm premature rupture of membranes: a systematic review and network meta-analysis.
Lin LL, Hung JN, Shiu SI, et al. · Am J Obstet Gynecol MFM 2023 · Systematic Review, Network Meta-Analysis
- Efficacy of topical treatments for mild-to-moderate acne: A systematic review and meta-analysis of randomized control trials.
Kakpovbia EE, Young T, Milam EC, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review, Network Meta-Analysis
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.